ClinicalTrials.gg
RecruitingNCT07563699Updated Aug 20, 2026

Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus

A Phase 1/2 interventional study of SG Depot 2 mg and SG Depot 4 mg in Diabete Type 2, sponsored by Mapi Pharma Ltd.. Recruiting at 1 site in Israel. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Mapi Pharma Ltd. · Phase 1/2, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 223 studies in Diabetes Mellitus, Type 2 with a site in Israel — 10 open to participants now, 16 under way, 7 of them phase 3. Diabetes Mellitus, Type 2 · Israel.

Planned enrollment
185th of 197
24 · median 343
Started
2026
with 3 others
Phase 1/2
3 of 223
1 open now
Primary completion
2028-05
later than 9 of 15 live
Registered
221st of 223
by date

Among the 223 studies in Diabetes Mellitus, Type 2 with a site in Israel, this one is the 185th largest by planned enrollment of the 197 interventional ones that give a count, is one of 4 that started in 2026, is one of 3 in phase 1/2, reaches primary completion later than 9 of the 15 other live ones, and was the 221st registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

10 of the 223 studies in Diabetes Mellitus, Type 2 with a site in Israel are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 223 studies in Diabetes Mellitus, Type 2 with a site in Israel, or all of them as a file.
02

Study summary

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is an approved and well-established therapy for type 2 diabetes mellitus (T2DM), providing both robust glycemic control and weight reduction. Semaglutide Depot, is a long-acting formulation of semaglutide, designed for once every four weeks administration, intended to reduce treatment burden, and improve adherence supporting sustained glycemic control over time.

This Phase I/Ila dose escalation study design to evaluate the safety, tolerability, pharmacokinetics and efficacy of Semaglutide Depot in adults with T2DM.

Read the detailed description

Study Title:

A Prospective, Multicenter, Open-Label, Dose Escalation Phase I/Ila Study to Assess the Safety, Tolerability, and Efficacy of Semaglutide Depot in Subjects with Type 2 Diabetes Mellitus

Background:

Type 2 diabetes mellitus (T2DM) is a chronic condition in which the body cannot properly use insulin, leading to elevated blood glucose levels. It is often associated with overweight or obesity and can lead to serious complications if not well controlled.

Semaglutide, is a GLP 1 receptor agonist, that helps lower blood glucose by increasing insulin secretion, reducing glucagon (a hormone that raises blood glucose), slowing gastric emptying, and reducing appetite. In addition to improving glycemic control, it also supports weight loss and has demonstrated cardiovascular benefits. Semaglutide is already approved in several formulations (examples: Ozempic® for type 2 diabetes and Wegovy® for weight management), but these require once-weekly injections.

Semaglutide Depot (SG Depot) is a new, long-acting formulation developed by Mapi Pharma Ltd. It is designed to be injected once every 4 weeks (once monthly), which may make treatment easier and improve adherence for people with diabetes.

Study Design:

  • Type: Phase I/Ila, open label, dose escalation study, prospective study
  • Sponsor: Mapi Pharma Ltd., Ness Ziona, Israel
  • Sites: Tel Aviv, Israel
  • Participants: Up to 24 adults with type 2 diabetes
  • Groups: Participants will be divided into 4 sequential dose cohorts: 2 mg, 4 mg, 6 mg and 8 mg
  • Dose escalation: will be allowed only after review of safety data
03

Conditions studied

  • Diabete Type 2

Keywords

  • Diabetes
  • Semaglutide Depot
  • Long-acting semaglutide
  • SG Depot
  • semaglutide LAI
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18-64 years with T2DM, 25-35 kg/m2
  2. On stable Semaglutide 1 mg weekly and for at least 3 months
  3. \<8%, ≥60 ml/minute
  4. For women: either non- or agreement to use acceptable

Exclusion criteria

Exclusion Criteria:

  1. Participation in another drug clinical study within 3 months
  2. History of cardiovascular or cerebrovascular disease
  3. Neuropathy or retinopathy or macular edema necessitating medical treatment
  4. Type 1 diabetes
  5. Unstable weight (> 5% change in the last 3 months)
  6. Current use of insulin and /or sulfonylureas and/or glinides
  7. Known to Semaglutide (per FDA-approved Semaglutide label)
  8. Recent therapy (within 90 days) or chemotherapy for within 5 years
  9. Moderate or severe hepatic impairment, ( or AST> 2 x (ULN)
  10. Severe hypertriglyceridemia (triglycerides >500 mg/dl)
  11. Pregnant or breast feeding
  12. Any condition that may increase risk or interfere with study participation (per Investigator judgement)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Cohort 1 - SG Depot 2 mg

    Drug: SG Depot 2 mg

  • Experimental
    Cohort 2 - SG Depot 4 mg

    Drug: SG Depot 4 mg

  • Experimental
    Cohort 3 - SG Depot 6 mg

    Drug: SG Depot 6 mg

  • Experimental
    Cohort 4 - SG Depot 8 mg

    Drug: SG Depot 8 mg

Interventions

  • DrugSG Depot 2 mg

    2 mg administered subcutaneously (s.c., under the skin) once every 4 weeks

  • DrugSG Depot 4 mg

    4 mg administered subcutaneously (s.c., under the skin) once every 4 weeks

  • DrugSG Depot 6 mg

    6 mg administered subcutaneously (s.c., under the skin) once every 4 weeks

  • DrugSG Depot 8 mg

    8 mg administered subcutaneously (s.c., under the skin) once every 4 weeks

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. The rate of treatment-associated adverse events (AEs)

    Time frame: Through study completion, up to 28 weeks for each subject

  2. Plasma concentration of semaglutide

    Time frame: Through study completion, up to 28 weeks for each subject

Secondary outcomes

  1. Change in HbA1c

    Time frame: Baseline (week 0), week 12

  2. Change in fasting plasma glucose from baseline

    Time frame: Baseline (week 0), week 12

  3. Change in body weight from baseline

    Time frame: Baseline (week 0), week 12

  4. The maximal tolerated dose (MTD) of SG Depot

    Time frame: Through study completion, up to 28 weeks for each subject

07

Study locations

1 of 1 sites recruiting
  • Mapi pharma Investigational Site ISR001
    Tel Aviv, 6423906, Israel
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for May 2028, 21 months after the start.

Of 41 phase 1/2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 71. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
May 4, 2026
StartActual
Aug 9, 2026
Primary completionEst.
May 2028
CompletionEst.
Jun 2028
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07563699
Lead sponsor
Mapi Pharma Ltd.
Responsible party
Sponsor
First posted
May 4, 2026
Start date
Aug 9, 2026
Primary completion
May 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Aug 20, 2026

Study contacts

Roy Eldor, Professor
Contact
roye@tlvmc.gov.il
972-36974243

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion